Search

Displaying results 2091 - 2100 of 3889 in total
  1. Drug

    VS-4718

    go.drugbank.com/drugs/DB15273
    Investigational

    VS-4718 is under investigation in clinical trial NCT02215629 (Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia).

  2. Drug

    Tefinostat

    go.drugbank.com/drugs/DB15321
    Investigational

    Tefinostat is under investigation in clinical trial NCT02759601 (Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)).

  3. Drug

    Pomaglumetad methionil

    go.drugbank.com/drugs/DB05096
    Investigational

    Further studies are planned or are ongoing to learn more about the safety and effectiveness, including determining an optimal therapeutic dose for LY2140023.

  4. Drug

    Bromus secalinus pollen

    go.drugbank.com/drugs/DB10836
    Approved

    Bromus secalinus pollen is the pollen of the Bromus secalinus plant. Bromus secalinus pollen is mainly used in allergenic testing.

    Mixtures: Treatment Set TS333938, Treatment Set TS128872
  5. Drug

    Typha latifolia pollen

    go.drugbank.com/drugs/DB10860
    Approved

    Typha latifolia pollen is the pollen of the Typha latifolia plant. Typha latifolia pollen is mainly used in allergenic testing.

    Mixtures: Treatment Set TS333938, Treatment Set TS128872
  6. Drug

    Influenza A virus A/Brisbane/02/2018 IVR-190 (H1N1) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB15515
    Approved

    A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposin...

    Mixtures: FLUZONE High-Dose
  7. Drug

    Insulin icodec

    go.drugbank.com/drugs/DB16693
    ApprovedInvestigational

    [L50758,A263818] Insulin icodec was approved by Health Canada in March 2024 for the treatment of adult patients with type 1 or 2 diabetes mellitus,[L50758] and was subsequently approved by the EMA in

  8. Drug

    Agalsidase beta

    go.drugbank.com/drugs/DB00103
    ApprovedInvestigational

    While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.

  9. Drug

    Artemisia vulgaris pollen

    go.drugbank.com/drugs/DB10372
    Approved

    Artemisia vulgaris pollen is the pollen of the Artemisia vulgaris plant. Artemisia vulgaris pollen is mainly used in allergenic testing.

    Mixtures: Treatment Set TS128872, Treatment Set TS343826
  10. Drug

    Faricimab

    go.drugbank.com/drugs/DB15303
    ApprovedInvestigational

    However, another set of factors, the Tie/Ang axis, comprising the transmembrane Tie-2 receptor and its soluble ligands Ang-1 and Ang-2, has been shown to play critical roles in mediating VEGF-A-induced